Literature DB >> 15707701

Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications.

E Bastiaannet1, J C Beukema, H J Hoekstra.   

Abstract

Adjuvant radiation treatment following lymph node dissection in the melanoma patient has been suggested and investigated in an attempt to gain regional control and improve survival. In this review we discussed the treatment, the loco-regional control, disease-free and survival rates and complications. Historically melanoma has been thought of as a relatively radioresistant tumour. Nowadays, radiation delivered according to the hypofractionated schedule is the most used, although there are no data to confirm that this schedule improves the therapeutic impact. Almost all the reviewed studies were retrospective, which could have led to an underestimation of the true incidence of the treatment toxicity and morbidity. Adjuvant radiotherapy after lymph node dissection for metastases of melanoma seems to improve loco-regional control without improving overall survival. The available data indicate the need for improved regional control rates in patients with extranodal extension, multiple involved nodes (more than three) and patients with large involved nodes (larger than 3 cm). The complications seem manageable and consist mainly of fibrosis and edema.

Entities:  

Mesh:

Year:  2004        PMID: 15707701     DOI: 10.1016/j.ctrv.2004.09.005

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  13 in total

Review 1.  The role of radiation therapy in the management of cutaneous melanoma.

Authors:  Charlene E Kan; David B Mansur
Journal:  Melanoma Manag       Date:  2016-02-24

2.  Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2012-03-10

3.  The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.

Authors:  Hasan H Danish; Kirtesh R Patel; Jeffrey M Switchenko; Theresa W Gillespie; Jaymin Jhaveri; Mudit Chowdhary; Mustafa Abugideiri; Keith A Delman; David H Lawson; Mohammad K Khan
Journal:  Melanoma Res       Date:  2016-12       Impact factor: 3.599

4.  Primary malignant melanoma of the lung with rapid progression.

Authors:  Ryo Maeda; Noritaka Isowa; Hideyuki Onuma; Hiroshi Miura; Hirokazu Tokuyasu; Yuji Kawasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-12

5.  A genomic screen identifies TYRO3 as a MITF regulator in melanoma.

Authors:  Shoutian Zhu; Heiko Wurdak; Yan Wang; Anna Galkin; Haiyan Tao; Jie Li; Costas A Lyssiotis; Feng Yan; Buu P Tu; Loren Miraglia; John Walker; Fanxiang Sun; Anthony Orth; Peter G Schultz; Xu Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

6.  Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.

Authors:  S Kruijff; E Bastiaannet; A H Brouwers; W B Nagengast; M J Speijers; A J H Suurmeijer; G A Hospers; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2011-08-23       Impact factor: 5.344

7.  S-100B concentrations predict disease-free survival in stage III melanoma patients.

Authors:  S Kruijff; E Bastiaannet; A C Muller Kobold; R J van Ginkel; A J H Suurmeijer; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2009-12       Impact factor: 5.344

8.  Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites?

Authors:  K P Wevers; E Bastiaannet; H P A M Poos; R J van Ginkel; J T Plukker; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2012-05-17       Impact factor: 5.344

9.  Immune correlates of melanoma survival in adoptive cell therapy.

Authors:  Agnes Fermin Lee; Peter A Sieling; Delphine J Lee
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

10.  Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2.

Authors:  Zhenhua Ding; Sun Jian; Xuebiao Peng; Yimin Liu; Jianyu Wang; Li Zheng; Chengshan Ou; Yinghui Wang; Weixia Zeng; Meijuan Zhou
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.